amyloid beta precursor protein binding family A member 3Genealiases: MGC:15815 · X11L2 · mint3
Q-omics provides the consensus-scored APBA3 profile across patient tissues and cancer cell-line models. APBA3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, APBA3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, APBA3 RNA expression shows 18,740 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where APBA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for APBA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes APBA3 survival associations across molecular data types. APBA3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible APBA3 RNA expression–survival associations across cancer types. High APBA3 expression shows unfavorable associations in ACC, UVM, KICH and LGG, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for APBA3 RNA expression.
This table summarizes APBA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for APBA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. APBA3 shows higher tumor expression in COAD, KIRC, HNSC, LIHC, STAD and BLCA. The COAD box plot shows higher APBA3 RNA expression in tumor versus normal tissue (log2 FC = +0.889, t-test p < 0.001).
This table shows molecular features associated with APBA3 in patient tissues and cancer cell lines. In patient samples, APBA3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, APBA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
